Sharechat Logo

Green Cross Health first-half profit falls 2% as costs rise

Tuesday 25th November 2014

Text too small?

Green Cross Health, formerly known as PharmacyBrands, posted a 2 percent decline in first half profit as higher wage and lease costs offset a pickup in sales.

Profit was $6.9 million in the six months ended Sept. 30, down from $7.1 million a year earlier, the Auckland based company said in a statement. Sales rose to $134.8 million from $127 million.

The owner of the Life Pharmacy and Unichem pharmacy chains has been widening its portfolio of businesses, agreeing this month to acquire Access Homehealth, a not for profit home healthcare services company. That adds to its purchase of medical centre business Peak Primary and a 50 percent stake in in community nursing and health care business Total Care Health.

"Our strategy of being an integrated primary care provider remains a key focus for the  board," said chairman Peter Merton.

Pharmacy retail sales from total stores rose 5 percent from a year earlier, while medical profit rose by 18 percent, the company said.

"The key drivers for this have been the rebranding of the groups pharmacies with all but a handful of pharmacies now under the Life Pharmacy and Unichem brands," the company said.

It will pay a first-half dividend of 3.5 cents a share. Shares of Green Cross rose 4.3 percent to $2.17 and have gained 66 percent this year.

 

 

 

 

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors